Analysts Estimate Report : What to Look Out for CymaBay Therapeutics (NASDAQ:CBAY)

Earnings results for CymaBay Therapeutics (NASDAQ:CBAY)

CymaBay Therapeutics Inc. is estimated to report earnings on 03/11/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.2. The reported EPS for the same quarter last year was $-0.35.

Analyst Opinion on CymaBay Therapeutics (NASDAQ:CBAY)

12 Wall Street analysts have issued ratings and price targets for CymaBay Therapeutics in the last 12 months. Their average twelve-month price target is $12.77, predicting that the stock has a possible upside of 158.23%. The high price target for CBAY is $20.00 and the low price target for CBAY is $9.00. There are currently 11 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of “Buy.”

CymaBay Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.08, and is based on 11 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $12.77, CymaBay Therapeutics has a forecasted upside of 158.2% from its current price of $4.95. CymaBay Therapeutics has only been the subject of 1 research reports in the past 90 days.

Dividend Strength: CymaBay Therapeutics (NASDAQ:CBAY)

CymaBay Therapeutics does not currently pay a dividend. CymaBay Therapeutics does not have a long track record of dividend growth.

Insiders buying/selling: CymaBay Therapeutics (NASDAQ:CBAY)

In the past three months, CymaBay Therapeutics insiders have not sold or bought any company stock. Only 4.00% of the stock of CymaBay Therapeutics is held by insiders. 84.28% of the stock of CymaBay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Earnings and Valuation of CymaBay Therapeutics (NASDAQ:CBAY

Earnings for CymaBay Therapeutics are expected to decrease in the coming year, from ($0.71) to ($1.01) per share. The P/E ratio of CymaBay Therapeutics is -5.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of CymaBay Therapeutics is -5.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. CymaBay Therapeutics has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

More latest stories: here